Yoshio Ogawa

Yoshio Ogawa

Auto-generated profile, based on publicly available information

Yoshio Ogawa

Department of Urology, Showa Medical University Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
KKKuniko Kusama-Eguchi
Kuniko Kusama-Eguchi
TMTakaaki Miyano
Takaaki Miyano
MYMakoto Yamamoto
Makoto Yamamoto
ASAtsuhiro Suda
Atsuhiro Suda
YIYoshihisa Ito
Yoshihisa Ito
TKTadashi Kusama
Tadashi Kusama

1 January 2020 in Urology Research and Practice
Verified
Journal Article
Closed access
SNSat Prasad Nepal
Sat Prasad Nepal
TNTakehiko Nakasato
Takehiko Nakasato
YOYoshio Ogawa
Yoshio Ogawa
MNMichio Naoe
Michio Naoe
TSTakeshi Shichijo
Takeshi Shichijo
MOMadoka Omizu
Madoka Omizu
Objective: This study aimed to assess the relationship of the prostate cancer and Gleason scores (GSs) or ISUP Grade system with prostate volume (PV) as assessed by magnetic resonance imaging (MRI) cognitive biopsy and standard biopsy. Material and methods: Data were collected from 659 patients who underwent MRI cognitive biopsy and standard biopsy from January 2014 to January 2018. The biopsies were performed because of increased prostate-specific antigen (PSA) levels (>4 ng/mL) and/or abnormal digital rectal examination findings. Transrectal ultrasound was used to measure PV. Results: Prostate cancer detection rates in patients with increased PVs of ≤40 cc and >40 cc were 68.8% and 51.6% (p40 cc were 68% and 73%, and 22.3% and 37.8%, respectively, for those with ISUP Grade group ≥4 (Gleason score ≥8) (p=0.003). Among the patients with PV>40 cc, univariate logistic regression showed a significant relationship between ISUP Grade group ≥2 and PSA, free/total PSA, PSA density, and MRI (p40 cc. Conclusion: Although the detection rates of prostate cancer decreased as PV increased, the detection of prostate cancer aggressiveness increased as PV increased. This increase in high ISUP Grade lesions with the rise in PV is due to the use of MRI during prostate biopsy with standard biopsy. Cite this article as: Nepal SP, Nakasato T, Ogawa Y, Naoe M, Shichijo T, Maeda Y, et al. Prostate cancer detection rate and Gleason score in relation to prostate volume as assessed by magnetic resonance imaging cognitive biopsy and standard biopsy. Turk J Urol 2020; 46(6): 449-54.

10 December 2005 in Journal of Natural Medicines
Verified
Journal Article
Closed access
PDF file
KKKuniko Kusama-Eguchi
Kuniko Kusama-Eguchi
ASAtsuhiro Suda
Atsuhiro Suda
FIFumio Ikegami
Fumio Ikegami
TKTadashi Kusama
Tadashi Kusama
YOYoshio Ogawa
Yoshio Ogawa
KWKazuko Watanabe
Kazuko Watanabe

1 April 2021 in Radiology Case Reports
Verified
Journal Article
Open access
SNSat Prasad Nepal
Sat Prasad Nepal
TSTakeshi Shichijo
Takeshi Shichijo
YOYoshio Ogawa
Yoshio Ogawa
TNTakehiko Nakasato
Takehiko Nakasato
YNYoshihiro Nakagami
Yoshihiro Nakagami
MMMoyuru Mizunuma
Moyuru Mizunuma
Segmental testicular infarction is a rare condition. Patients present with clinical features similar to torsion and testicular tumors, with most undergoing surgery. A 55-year-old male patient presented with left scrotal pain. We did a Doppler ultrasonogram and magnetic resonance imaging to diagnose his condition and rule out testicular torsion and tumor. We decided not to operate and asked the patient for follow-up. There was no pain in the left testis, and magnetic resonance imaging showed a reduction in the left testicular lesion after 4 months.

26 December 2024 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Open access
PDF file
MSMiki Takenaka Sato
Miki Takenaka Sato
TATakuya Araki
Takuya Araki
HYHideaki Yashima
Hideaki Yashima
YIYuya Ishikawa
Yuya Ishikawa
JMJun Morita
Jun Morita
MKMari Kogo
Mari Kogo
Purpose The blood concentrations of some tyrosine kinase inhibitors are known to decrease with long-term administration. We evaluated the variability in the serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment. Methods This study prospectively recruited patients who received sunitinib for metastatic renal cell carcinoma at the Showa University Hospital between March 2020 and January 2022. Bivariate correlations between the serum concentration/dose (C/D) ratios of sunitinib and its metabolites (i.e., N-desethyl sunitinib and sunitinib N-oxide) and treatment duration were evaluated using Pearson’s correlation coefficient. Results Seven patients were enrolled, and 79 blood samples were collected. Among six patients who received sunitinib for > 1 year, three showed a decreasing trend in the C/D ratio of sunitinib (Pt1: r = -0.608, p = 0.047; Pt2: r = -0.555, p = 0.077; Pt6: r = -0.590, p = 0.073). In these patients, the median annual decrease in the C/D ratio of sunitinib was 55.8% (26.5–63.2%). Additionally, two of the three patients also showed a decrease in the C/D ratio of N-desethyl sunitinib. The ratio of N-desethyl sunitinib/sunitinib concentration at baseline and the end of follow-up was similar between the C/D-decreased and C/D-non-decreased groups. Conclusion This study showed that the C/D ratio of sunitinib decreased by half over time in half of the patients who received long-term sunitinib treatment despite continuing the same dose. Therefore, serum concentrations of sunitinib and its metabolites should be monitored periodically in patients receiving long-term treatment to prevent decrease in serum sunitinib concentrations.

24 November 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MSMiki Takenaka Sato
Miki Takenaka Sato
AIAyuki Ida
Ayuki Ida
YKYuki Kanda
Yuki Kanda
KTKaori Takano
Kaori Takano
MOMasayuki Ohbayashi
Masayuki Ohbayashi
MKMari Kogo
Mari Kogo
Background: The association between the combination of platelet count and neutrophil–lymphocyte ratio (COP-NLR) at the time of adverse events during sunitinib treatment and prognosis is unclear, and prognostic models combining the prognostic factors of sunitinib have not been well studied. Thus, we developed a prognostic model that includes the COP-NLR to predict the prognosis of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Methods: We performed a retrospective cohort study of 102 patients treated with sunitinib for mRCC between 2008 and 2020 in three hospitals associated with Showa University, Japan. The primary outcome was overall survival (OS). The collected data included baseline patient characteristics, adverse events, laboratory values, and COP-NLR scores within the first 6 weeks of sunitinib treatment. Prognostic factors of OS were analyzed using the Cox proportional hazards model. The integer score was derived from the beta-coefficient (β) of these factors and was divided into three groups. The survival curves were visualized using the Kaplan–Meier method and estimated using a log-rank test. Results: The median OS was 32.3 months. Multivariable analysis showed that the number of metastatic sites, Memorial Sloan Kettering Cancer Center risk group, number of metastases, non-hypertension, modified Glasgow Prognostic Score, and 6-week COP-NLR were significantly associated with OS. A higher 6-week COP-NLR was significantly associated with a shorter OS (p < 0.001). The β values of the five factors for OS were scored (non-hypertension, mGPS, and 6-week COP-NLR = 1 point; number of metastatic sites = 2 points; MSKCC risk group = 3 points) and patients divided into three groups (≤ 1, 2–3, and ≥ 4). The low-risk (≤ 1) group had significantly longer OS than the high-risk (≥ 4) group (median OS: 99.0 vs. 6.2 months, p < 0.001). Conclusions: This study showed that the COP-NLR within the first 6 weeks of sunitinib treatment had a greater impact on OS than the COP-NLR at the start of sunitinib treatment. The developed prognostic model for OS, including the 6-week COP-NLR, will be useful in decision-making to continue sunitinib in the early treatment stage of patients with mRCC.